• Publications
  • Influence
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Etoricoxib represents a novel agent that selectively inhibits COX-2 with 106-fold selectivity in human whole blood assays in vitro and with the lowest potency of inhibition ofCOX-1 compared with other reported selective agents. Expand
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor
The time‐dependent inhibition by DFU was decreased by co‐incubation with arachidonic acid under non‐turnover conditions, consistent with reversible competitive inhibition at the COX active site. Expand
Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.
A system for the evaluation of vitreal inflammatory activity in patients with intermediate and posterior uveitis is presented and a series of photographs representing various degrees of fundus vitreal haze is depicted. Expand
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Rofecoxib is a novel COX-2 inhibitor with a biochemical and pharmacological profile clearly distinct from that of current nonsteroidal anti-inflammatory drugs and represents a new therapeutic class of anti- inflammatory agents for the treatment of the symptoms of osteoarthritis and rheumatoid arthritis with improved gastrointestinal tolerability. Expand
Ocular and central nervous system lymphoma: clinical features and diagnosis
The prognosis of the disease remains poor, however, the new diagnostic tools and therapeutic strategies may improve the diagnostic delay and the survival outcome. Expand
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.
The induction of EAU in the mouse is reported, which has hitherto been considered a species refractory to EAU, with two retinal Ag, the retinal soluble Ag and the interphotoreceptor retinoid-binding protein, and the EAU model in mice was found to differ in several respects. Expand
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.
Recent studies have shown that there are two isoforms of cyclooxygenases. The constitutive form, cyclooxygenase 1 (COX-1), is believed to be involved in the maintenance of physiological functions. AExpand
Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
The occurrence of PCNSL in the eye was strongly associated with elevated vitreous levels of IL-10 relative to levels ofIL-6, and among patients with diagnosedPCNSL, malignant cells were significantly more likely to be present in CSF when levels of Il-10 exceeded those of IL -6. Expand
Intraocular lymphoma. Clinical and histopathologic diagnosis.
The prompt, appropriate handling of specimens and review by an experienced cytopathologist are critical to the diagnosis of intraocular lymphoma, which is associated with significant morbidity and mortality. Expand
PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
The studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compounds trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacological actions of a pre-synaptic alpha(2)-adrenoceptor inhibition. Expand